Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy by unknown
ORIGINAL PAPER
Tissue factor is an angiogenic-specific receptor for factor
VII-targeted immunotherapy and photodynamic therapy
Zhiwei Hu1,2 • Jijun Cheng2,5 • Jie Xu2,6 • Wolfram Ruf3 • Charles J. Lockwood4
Received: 19 July 2016 / Accepted: 25 October 2016 / Published online: 2 November 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Identification of target molecules specific for
angiogenic vascular endothelial cells (VEC), the inner
layer of pathological neovasculature, is critical for dis-
covery and development of neovascular-targeting therapy
for angiogenesis-dependent human diseases, notably can-
cer, macular degeneration and endometriosis, in which
vascular endothelial growth factor (VEGF) plays a central
pathophysiological role. Using VEGF-stimulated vascular
endothelial cells (VECs) isolated from microvessels,
venous and arterial blood vessels as in vitro angiogenic
models and unstimulated VECs as a quiescent VEC model,
we examined the expression of tissue factor (TF), a
membrane-bound receptor on the angiogenic VEC models
compared with quiescent VEC controls. We found that TF
is specifically expressed on angiogenic VECs in a time-
dependent manner in microvessels, venous and arterial
vessels. TF-targeted therapeutic agents, including factor
VII (fVII)-IgG1 Fc and fVII-conjugated photosensitizer,
can selectively bind angiogenic VECs, but not the quies-
cent VECs. Moreover, fVII-targeted photodynamic therapy
can selectively and completely eradicate angiogenic VECs.
We conclude that TF is an angiogenic-specific receptor and
the target molecule for fVII-targeted therapeutics. This
study supports clinical trials of TF-targeted therapeutics for
the treatment of angiogenesis-dependent diseases such as
cancer, macular degeneration and endometriosis.
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Introduction
Angiogenesis, the formation of new blood vessels from
existing blood vessels, is a common and critical patho-
logical process in many human diseases [1], including but
not limited to cancer, age-related macular degeneration
(AMD), endometriosis and rheumatoid arthritis. For
example, in cancer, the newly formed blood vessels, usu-
ally termed as tumor angiogenic vessels or tumor neovas-
culature, can be differentiated from normal (resting,
quiescent) vessels in normal tissues in morphology (vas-
cular and endothelial shapes), and function (increased
permeability) [2, 3]. As such, tumor neovasculature pro-
vides not only nutrients and oxygen for cancer cells to
proliferate, but also serves as a conduit for cancer cells to
metastasize. Thus, the tumor neovasculature is a key target
for development of therapeutic agents. The search for
biomarkers as target molecules specific for angiogenic
vascular endothelial cells (VEC), the inner layer of
pathological neovasculature, is promising and critical in
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developing novel neovascular-targeting therapies for these
common human diseases [1].
One potential approach to eliminating pathological
neovascularization involves attacking the subset of vascu-
lar endothelial cells that are angiogenic, via a cell-type-
specific surface molecule coupled to a cell-killing agent.
Based on the in vivo observation of TF expression on
tumor vascular endothelial cells in breast cancer tissues
from patients [4] and some mouse models of human tumor
xenografts [5–7], we have begun developing such an
approach using tissue factor (TF), a 47-kDa membrane-
bound receptor [4, 8–11], as the target molecule on
angiogenic VECs. To assemble this TF-directed treatment,
we used, as the starting molecule, the principal ligand of
TF, factor VII (fVII) [12]. To eliminate the coagulation
activity of zymogenic fVII, a coagulation active site lysine
341 was replaced by an alanine (thereafter containing the
mutation of K341A in fVII polypeptides unless specified)
using site-directed mutagenesis [5, 13, 14]. Using this
strategy, we have pursued two different therapeutic
approaches; immunotherapy (by fusing fVII to an IgG1 Fc
as an antibody-like immunoconjugate, i.e., fVII/IgG1 Fc,
also called ICON) [5, 14] and photodynamic therapy (PDT)
(by chemically conjugating fVII peptides with photosen-
sitizers (PS), fVII/PS, for fVII-targeted PDT, abbreviated
as fVII-tPDT) [15, 16] for the treatment of cancers
including melanoma [5, 13], prostate [14], head and neck
[17], breast [7, 15, 16] and lung [6], as well as age-related
macular degeneration (AMD) [18–20] and endometriosis
[21] in preclinical animal models and in phase I and II
clinical trials for AMD patients (NCT01485588) [22].
In vivo data confirm that the TF-targeted agents ICON and
fVII-tPDT can selectively eradicate pathological neovas-
culature in cancer [13, 23], AMD [18–20] and
endometriosis [21]. However, it remains unclear which
angiogenic growth factor induces TF expression commonly
detected in these pathological angiogenesis-dependent
malignancy and non-malignant diseases, whether TF is also
selectively expressed by in vitro angiogenic VEC models
and whether TF-targeted agents can selectively eradicate
in vitro models of angiogenic VECs via targeting TF
without harming quiescent VECs. This study is designed to
address these questions by identifying a common angio-
genic growth factor (for example, VEGF) in these angio-
genic-dependent diseases, examining TF expression on
in vitro models of angiogenic and quiescent VECs and then
testing the selectivity and effectiveness of TF-targeted
agents (ICON and fVII-PS) for binding and killing the
in vitro angiogenic VECs.
Vascular endothelial growth factor (VEGF) plays a
central role in angiogenesis-dependent cancer and non-
malignant human diseases [24], such as macular degener-
ation [25], rheumatoid arthritis [26] and endometriosis
[27]. Specifically, VEGF stimulates angiogenesis by
binding to VEGR receptors on VECs in the pathological
neovasculature (usually micro- or capillary vessels) in
those angiogenesis-dependent diseases. In humans, there
are three major types of blood vessels, namely micro- or
capillary vessels, veins and arteries. Accordingly, VEC, the
inner layer of blood vessels, can be isolated from
microvessels, venous and arterial vessels. It is previously
known that VEGF can induce TF expression on human
umbilical vein endothelial cells (HUVEC), a commonly
used VEC model in angiogenesis studies. To better mimic
pathological angiogenesis, an ideal angiogenic VEC model
should be derived from micro- or capillary vessels. This
study is designed to investigate whether angiogenic VECs
from micro- or capillary vessels express TF upon VEGF
stimulation and whether fVII-dependent therapies target
non-pathological (quiescent) endothelial cells using VEGF-
stimulated and unstimulated VECs as in vitro models.
Therefore, in the current study, we examined the expres-
sion patterns of TF on in vitro models of angiogenic and
quiescent VECs from three types of blood vessels and
sought to rigorously assess the validity of the claim that
dimeric fVII-IgG1Fc (ICON) in immunotherapy and
monomer fVII peptide in PDT are selective and effective in
killing angiogenic VECs via TF targeting.
Materials and methods
Cell culture
HMVECs (Lonza), HUVEC (generously provided by the
Yale Vascular Biology and Therapeutics (VBT) Program)
and HAEC (Lonza) were purchased and grown in growth
medium supplemented with heat-inactivated fetal bovine
serum (FBS, Sigma) and 19 penicillin and streptomycin
(Gibco), following the manufacturers’ protocols. Lung-
derived normal human microvascular endothelial cells
(HMVEC-LBI, simplified as HMVEC) were purchased
(Lonza). As assayed by the manufacturer, the HMVEC
cells were endothelial marker CD31 positive, lymphatic
endothelial marker podoplanin negative and muscle cell
marker alpha actin negative. These assay results confirmed
their origin of blood VEC. It was cultured in Lonza’s
growth medium, EBM-2 basal medium supplemented with
EGM-2 MV SingleQuot Kit supplements and growth fac-
tors (Lonza) and 20% FBS, propagated with the Reagent-
Pack Subculture Reagents (Lonza) containing the three
solutions, trypsin/EDTA, trypsin neutralizing solution, and
HEPES-buffered saline. HUVECs were grown in M199
growth medium supplemented with 20% heat-inactivated
FBS (HI-FBS) and 1:100 ECGS solution, as described [15].
HAECs (Lonza) were grown in EGM-2 medium
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supplemented with 10% HI-FBS. Cells are cultured at
37 C with 5% CO2. Human breast cancer MDA-MB-231
line was grown in DMEM supplemented with 10% FBS.
CHO-K1 lines were grown in F-12 K (ATCC) medium
with 10% FBS and 0.5 mg/ml G418 (Invitrogen), including
CHO-K1 cell lines stably expressing TF, EPCR or
TF ? EPCR. Untransfected CHO-K1 cells were used as
negative control for TF and EPCR and for generating a
stable CHO-K1/EPCR line by transfection with a plasmid
encoding EPCR (kind gift from Dr. Ruf).
Generation of in vitro angiogenic and quiescent
VEC models by VEGF stimulation
HMVECs (Lonza), HUVEC (Yale VBT group) and HAEC
(Lonza) were first seeded with 5 9 103 cells/cm2 cultured in
complete growth media with heat-inactivated FBS and
growth factors, either in 6-well microplates (1.25 9 105
cells per well for extraction of cell lysates for Western
blotting), 96-well microplates (1.5 9 103 cells in 100 ll per
well for cell ELISA and fVII-tPDT) or in 8-chamber slides
(3.5 9 103 cells in 500 ll per chamber for immunofluores-
cent staining and confocal microscopy), until 80–90% con-
fluence is reached. Prior to VEGF stimulation, the VECs
were washed 93 with HEPES-buffered saline to remove
trace of FBS and growth factors (to minimize their potential
effect on induction of TF and EPCR expression) and then
starved in serum-free and growth factors-free EBM-2 basal
medium (Lonza) or endothelial cell serum-free medium
(Invitrogen) overnight. The cells were then exchanged with
half of the same serum-free medium supplemented with a
final concentration of 1 nM VEGF (BD Biosciences), a
concentration that was previously tested for induction of TF
expression on HUVEC [28], for 2, 4, 6, 8 and 24 h as
angiogenic VEC models. The VECs were starved but were
not stimulated with VEGF as quiescent VEC control (0 h).
And then the VECs were used as in vitro angiogenic (1 nM
VEGF stimulation for 4 h as TF reaching the peak expression
at this time point) and quiescent VECmodels in experiments
withWestern blotting, confocal microscopy, cell ELISA and
fVII-tPDT treatment and mechanism studies.
Immunofluorescent staining and confocal
microscopic imaging
For confocal microscopy, the VECs grown on chamber
glass slides were fixed with 4% paraformaldehyde (PFA)
and then were immunostained for TF using mouse mono-
clonal antihuman TF (HTF1) (kind gift from William
Konigsberg) (clone HTF 1) [29], antihuman endothelial
marker CD31 PE conjugate (BD Biosciences) and nuclei
staining dye DAPI (Molecular Probes) for confocal
microscopy.
Protein samples of angiogenic and quiescent VECs
for Western blotting
For Western blotting, protein samples were extracted from
the VECs (HMVEC, HUVEC and HAEC) by TRIzol
reagent (Invitrogen) followed by immunoblotting for TF
and GAPDH expression using antihuman TF (HTF1) [29]
and anti-GAPDH (Research Diagnostic Inc) antibodies,
and the band intensities were normalizing to GAPDH using
NIH ImageJ analysis.
Cell ELISA and inhibitory cell ELISA
For cell ELISA, the VECs grown in 96-well plates were
assayed for binding of mfVII/hIgG1 Fc, mfVII/Sp and anti-
TF (HTF1) antibodies followed by anti-mfVII (for mfVII
proteins) and then by corresponding secondary antibody
HRP conjugates (antihuman IgG, anti-mouse IgG or anti-
rat IgG antibodies). For inhibitory cell ELISA, the VECs
were incubated first with anti-HTF or anti-EPCR antibodies
(clone RCR-379, Sigma, as control antibody) prior to
incubation with mfVII/hIgG1 Fc at molar ratios from 0.1:1
to 10:1 (antibody to fVII/IgG1 Fc).
We compared two anti-HTF antibodies, mouse mono-
clonal antihuman TF (HTF1) and goat polyclonal antihu-
man TF (goat anti-TF, American Diagnostica), for their
inhibitory effect on mfVII/IgG1 Fc binding to human
breast cancer MBA-MB-231 cell line, which was known to
express a high level of TF [15, 16]. For fVII blocking
experiments, we first stimulated HMVEC with 1 nM
VEGF for 4 h then fixed the cells. After blocking with 1%
BSA, we incubated the VEGF-stimulated HMVEC with
goat anti-TF (American Diagnostica) or mouse anti-TF
(HTF1) antibodies then added mfVII/hIg Fc. To determine
whether fVII is a ligand for TF, we developed an inhibitory
cell ELISA assay, in which angiogenic VEC (stimulated
with 1 nM VEGF for 4 h) was first fixed by 4%
paraformaldehyde (PFA) and subsequently blocked by
0.1–100 nM of inhibitory anti-HTF (goat anti-HTF) or
anti-EPCR (RCR-379), which blocks binding of EPCR
ligand to EPCR [30]. The procedure was terminated by
incubation with 10 nM mfVII/hIgG Fc (molar ratios
0.01:1–10:1, inhibitory antibody to mfVII/hIgG Fc) and
then with anti-hIgG HRP conjugate.
Production of mfVII/Sp- or mfVII/NLS-SnCe6
conjugates
The procedures have been described in detail [6, 15, 16].
Briefly, the mfVII/Sp protein is composed of murine
fVII(K341A), an S peptide (Sp) tag with a mutation at
D14 N and a polyhistidine tag (His tag) for protein
purification and detection (mfVII(K341A)/Sp(D14 N)/His,
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abbreviated as fVII/Sp [15, 16] for simplification). The
mfVII/NLS protein is composed of the coding sequences
for mfVII(K341A), 2 repeats of the wild-type nuclear
localization sequence (NLS) (PKKKRKVG) of SV40
T-antigen [31], a tyrosine residue (requisite for future
radioiodination imaging) and a His tag (mfVII(K341A)/
NLS/His, abbreviated as fVII/NLS). The fVII/Sp and fVII/
NLS proteins were produced using CHO-K1 producer cells
and purified using the Ni-NTA affinity resin as described
[15, 16]. The procedure for the conjugation of mfVII
proteins to photosensitizer SnCe6 was described [15, 16].
In vitro fVII-tPDT for HMVECs
For fVII-tPDT, HMVECs grown in 96-well plates were
incubated with 2 lM fVII/Sp-SnCe6 or fVII/NLS-SnCe6
for 90 min, which was previously optimized as the drug–
light interval for fVII-tPDT [16], then were irradiated
(635 nm, 36 J/cm2) with a 635-nm fiber-coupled diode
laser (BWF2-635-0.1-100-0.22, B&W Tek, Inc.). The flu-
orescence rate of the laser unit was measured by using a
laser power meter (LaserCheck, Coherent, Inc.) prior to
carrying out PDT. We used two assays to determine the
effect of fVII-tPDT, one was crystal violet assay staining
for monolayer membrane loss (overnight after fVII-tPDT)
and the other was clonogenic assay for observing longer-
term viability (10-14 days after fVII-tPDT), as described
[7, 15, 16, 32]. Briefly, HMVEC cells, uninduced or
induced by VEGF for 4 h, were washed with 19 HBSS
containing 1% BSA, incubated with different concentra-
tions of SnCe6-conjugated mfVII/Sp or mfVII/NLS, or free
SnCe6 in the incubation buffer (19 HBSS with 1% BSA
and 10 mM CaCl2), or no treatment in the buffer as con-
trols, and cultured for 90 min at 37 C. Then, the cells
were washed and refilled with the growth medium for laser
irradiation at 635 nm for 36 J/cm2.
Crystal violet staining and clonogenic assay
Crystal violet staining and clonogenic assays after PDT
were performed as described [15, 16]. Briefly for clono-
genic assay, HMVECs in 96-well plates after PDT were
cultured overnight, were transferred to a 60-mm dish and
were diluted at tenfold serial dilutions. The cell suspen-
sions were cultured for 12–14 days to allow colony for-
mation, followed by fixation and crystal violet staining at
the same condition used above for staining cells directly
after PDT. Visible colonies of more than 50 cells were
counted, and total cells in each original well, designated as
colony formation units # (CFU), were back calculated by
colony number times dilution factor. Percent colony for-
mation, in comparison with no-treatment controls, was
calculated as (colony # in experimental wells-average
colony # in no-treatment wells) 9 100%.
Apoptosis and necrosis assays for mechanisms
of in vitro PDT
Cells cultured in 96-well plate after PDT were immediately
washed with the HEPES buffer (10 mM HEPES, pH 7.4,
140 mM saline, 2.5 mM CaCl2), stained with 1:20 Annexin
V-FITC (Invitrogen), for phosphastidylserine, and 1 lg/ml
of propidium iodide (PI), for DNA, in the HEPES buffer
for 15 min at room temperature, and then washed and
refilled with in 19 DPBS. The cells were visualized and
photographed immediately under a fluorescent microscope.
Statistical analyses
All quantitative assays were done in duplicates to calculate
averages and standard deviation (mean ± SD). The half
maximal effective concentrations (EC50) of fVII-tPDT and
ntPDT were calculated by the best-fit linear regression or
nonlinear one-phase decay equations using Prism software
(GraphPad). P values were calculated using 2-way
ANOVA with multiple comparisons test using Prism soft-
ware (GraphPad), as specified in each figure legend.
Results
To test for expression of angiogenic surface receptors, we
used VEGF to generate angiogenic VEC models in vitro,
and tested for the presence of TF on primary human VECs
derived from three major types of mammalian vessels: (1)
HMVEC, human microvascular endothelial cells; (2)
HUVEC, human umbilical venous endothelial cells; and
(3) HAEC, human aortic endothelial cells.
We first examined the time course of TF expression on
angiogenic and quiescent HMVEC (Fig. 1a), HUVEC
(Fig. 1b) and HAEC (Fig. 1c). The Western blotting results
in Fig. 1 showed that (1) TF protein, reported MW 47 kDa,
shown in Fig. 1 as a band at*50 kDa, was not detected in
quiescent VEC (starved and unstimulated) (time
point = 0 h, red arrows in TF expression fold chart) from
all three VECs; (2) TF was detected in VEGF-treated
angiogenic VECs (HMVEC, HUVEC and HAEC) within
2 h of VEGF stimulation; (3) and peaked at 4–6 h, then
started decreasing at 6 h post-stimulation.
To confirm the time course of induced TF expression on
endothelial cells, we stained VEC for TF and the
endothelial marker CD31 and observed the stained VEC
under confocal microscope. The results in Fig. 1d showed
that TF was not detected on quiescent VEC (0 h). After
VEGF stimulation, however, TF expression was detected at
88 Angiogenesis (2017) 20:85–96
123
2 h with a peak in fluorescent intensity at 4–6 h followed
by a decrease that was still visible at 24 h.
Next, we examined the binding (specificity) of fVII
therapeutic agents to angiogenic VECs. To generate
angiogenic VEC with maximal TF expression, VECs were
incubated with 1 nM VEGF for 4 h based on the results in
Fig. 1. Confocal imaging confirmed that TF was expressed
on angiogenic HMVEC (Fig. 2a), HUVEC (Fig. 2c) and
HAEC (Fig. 2e) after 4 h stimulation with VEGF, but not
on resting VECs (Fig. 2b, d, f). Taken the results in Figs. 1
and 2, we conclude that TF is selectively expressed on
angiogenic VEC, which can be induced on VECs from all
three types of blood vessels (vein, microvessels and artery).
To assess the binding specificity of murine fVII/human
IgG1 Fc (mouse ICON) and murine fVII/Sp (simplified as
mfVII in Fig. 2) to angiogenic VECs, 4 h VEGF-stimulated
Fig. 1 TF is an angiogenic-specific receptor on endothelial cells. a–
c. Representative imaging of Western blots and expression fold
changes (normalized to GAPDH) for TF in HMVEC (a), HUVEC
(b) and HAEC (c) before (0 h) and after VEGF stimulation (2–24 h).
d Representative confocal imaging of TF (green) and endothelial
marker CD31 (red) expression on HMVEC before (0 h) and after
VEGF stimulation (2–24 h). Cell nuclei were counterstained by DAPI
(blue). Scale bars: 20 lm. p values were calculated by 2-way
ANOVA with multiple comparisons test. Data in a–c are presented as
Mean ± SD and representative of two independent experiments.
(Color figure online)
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VECs (Fig. 2g, i, k) and unstimulated VECs (Fig. 2h, i, j)
were analyzed by cell ELISA. To ensure that cell mem-
brane-bound mfVII/hIgG1 Fc was intact, we separately
used anti-mfVII and antihuman IgG Fc antibody horse-
radish peroxidase conjugates for detection of mfVII/hIgG1
Fc in the cell ELISA. The cell ELISA results in Fig. 2g, h, i
are summarized as follows. (1) A mouse monoclonal anti-
TF antibody (clone HTF1) demonstrated that angiogenic
VECs expressed TF (HMVEC in Fig. 2g, HUVEC in
Fig. 2i and HAEC in Fig. 2k), whereas quiescent VECs do
not express TF (Fig. 2h, j, l). The TF results by cell ELISA
are consistent with the Western blotting results (Fig. 1) and
confocal imaging results (Fig. 2a, b, c, d, e, f). (2) Similar to
observations made with the anti-TF antibody, fVII agents,
either in dimeric (mfVII/hIgG1 Fc) or monomeric form
(mfVII), selectively bound all three angiogenic VEC types
(Fig. 2g, i, k, respectively). In contrast, fVII agents did not
bind to any of the quiescent VECs (Fig. 2h, 2j, l). Further,
results in Fig. 2f, g suggested that mfVII/hIgG1 Fc was
intact when binding to angiogenic HMVEC and HUVEC
since there was no difference between anti-mfVII and anti-
hIgG antibodies for detection of mfVII/hIgG1 Fc in cell
ELISA. These findings established that (1) TF is selectively
expressed on angiogenic VECs; (2) fVII agents selectively
bind angiogenic VECs, likely reflecting their binding to TF
(See Figs. 1 and 2).
To confirm that selective binding of fVII agents to
angiogenic VECs is mediated by TF, we carried out
experiments that directly evaluated the ability of anti-TF
antibodies to inhibit fVII binding to TF on angiogenic
VECs. Two antihuman TF antibodies, mouse monoclonal
antibody HTF1 and a goat polyclonal antibody (goat anti-
HTF) (American Diagnostica), which were known to be
able to block TF coagulation [29, 33], were compared for
their relative inhibition of fVII binding to TF. Initial
studies established that both anti-TF antibodies (p[ 0.05)
similarly bind to a breast cancer line (MDA-MB-231) that
expresses high levels of TF [16] (Fig. 3a). Subsequently,
Fig. 2 Selective binding of fVII agents to in vitro angiogenic VEC
models. a–f Representative confocal imaging of different expression
patterns of TF on in vitro angiogenic and quiescent VEC models.
HMVEC (a, b), HUVEC (c, d) and HAEC (e, f). g–l Selective
binding of fVII agents (mfVII/hIgG1 Fc and mfVII peptides) and anti-
TF antibody to angiogenic VECs (g, i, k), but not to quiescent VECs
(h, j, l). HMVEC (g, h), HUVEC (i, j) and HAEC (k, l). Scale bars in
a–f: 20 lm. p values were calculated by 2-way ANOVA with
multiple comparisons test. Data in g–l are presented as Mean ± SD
and representative of two independent experiments
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goat anti-HTF was found to display a significantly stronger
effect than HTF1 on inhibiting the binding of mfVII/hIgG1
Fc to MDA-MB-231 cancer cells (p\ 0.001) (Fig. 3b).
These observations suggested using goat anti-HTF as an
inhibitory antibody for the experiments described in
Fig. 3c, d, e.
Fig. 3 Selective binding of fVII agents to angiogenic VECs is
mediated by TF. a–b. Choice of anti-TF antibodies for inhibiting the
binding of fVII agent (mfVII/hIgG1 Fc) to TF. MDA-MB-231 is a
human breast cancer line with high level of TF expression and is used
here as a TF-expressing cell model. Two antihuman TF antibodies,
goat anti-HTF and mouse anti-HTF (Clone HTF1), display similar
binding to the MDA-MB-231 cells (a) but goat anti-TF antibody
shows stronger inhibitory effect than monoclonal HTF1 in blocking
mfVII/hIgG1 Fc binding to cancer cell TF (b). c–e Selective binding
of mfVII/hIgG1 Fc to angiogenic HMVEC (c), HUVEC (d) and
HAEC (e) can be completely blocked by goat anti-HTF, but not by
control antibody. f Representative Western blots using mfVII/hIgG1
Fc and hfVII/hIgG1 Fc to immune-precipitate their cognate receptor
TF (f). The negative control was the untransfected CHO-K1 cells.
Human IgG was an isotype control. p values were calculated by
2-way ANOVA with multiple comparisons test. Data in a–e are
presented as Mean ± SD and representative of two independent
experiments
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To determine whether fVII is a ligand for TF on in vitro
angiogenic VEC models, we developed an inhibitory cell
ELISA assay in which angiogenic VEC were first incu-
bated with various nanomolar concentrations of inhibitory
goat anti-HTF for blocking TF or anti-EPCR (RCR-379)
for blocking EPCR [30] as a control antibody, followed by
incubation with 10 nM mfVII/hIgG1 Fc (to generate molar
ratios 0.01:1–10:1, inhibitory antibody to mfVII/hIgG Fc).
The binding of fVII/IgG1Fc was detected with anti-hIgG
HRP conjugate. We found that goat anti-HTF completely
(at ratios of 1:1 and 10:1) or partially (at ratios of 0.01:1
and 0.1:1) inhibit the binding of mfVII/hIgG1 Fc to all
three angiogenic VECs (See Fig. 3c, d, e; HMVEC in
Fig. 3c, HUVEC in Fig. 3d and HAEC in Fig. 3e). By
contrast, control antibody did not inhibit fVII binding to
angiogenic VECs, demonstrating that on angiogenic VECs,
fVII acts via binding to TF. To further verify the specificity
of fVII agents to TF versus the endothelial protein C
receptor (EPCR) [34], we carried out immunoprecipita-
tion–Western blotting (IP–WB) analysis using stable CHO-
K1 cell lines expressing TF, EPCR, TF and EPCR and the
control was untransfected CHO-K1 cells [35]. The results
showed that mouse and human ICON could pull down TF
efficiently in the presence and absence of EPCR (Fig. 3f),
demonstrating that fVII agents (fVII/IgG1 Fc, ICON)
specifically bind to TF.
To determine whether fVII agents are selective and
effective in killing angiogenic VECs, we tested fVII-tPDT
using photosensitizer SnCe6-conjugated monomeric mfVII
peptides. We first confirmed that like goat anti-TF antibody
(Fig. 4a), PS-conjugated mfVII/Sp (Fig. 4b) and mfVII/
NLS (Fig. 4c) selectively binds to angiogenic HMVECs.
Then, we tested the effectiveness and selectivity of fVII-
tPDT for in vitro killing of angiogenic HMVEC using the
following assays:
1. The first assay was designed to observe immediate
effect of fVII-tPDT by using crystal violet staining and
photography under microscope for observation of
cellular morphology overnight after fVII-tPDT treat-
ment. We found that fVII-tPDT selectively and
effectively killed angiogenic HMVEC (see VEGF-
stimulated in Fig. 4d), whereas it had no obvious
effects on unstimulated, quiescent HMVEC (normal
VEC control). In contrast, nontargeted PDT (ntPDT)
under the same conditions as fVII-tPDT except using
free SnCe6 had no effect on killing angiogenic and
quiescent HMVEC (Fig. 4d).
2. The second test for the selectivity and effectiveness of
fVII-tPDT to angiogenic VECs was a clonogenic
assay, which is designed for observing longer-term cell
viability and proliferation. To target TF for photody-
namic therapy, we made two mfVII peptides, namely
mfVII/Sp and mfVII/NLS. Both are composed of
single-chain peptide of mature murine factor VII with
an active site mutation (K341A) followed by a
14-amino acid residue S tag (Sp) and a 13-aa nuclear
localization sequence (NLS) [6, 15], respectively. We
showed that two weeks after treatment with fVII-tPDT
using mfVII-SnCe6 conjugates, angiogenic HMVEC
did not form any colonies (See Fig. 4e), indicating that
fVII-tPDT was able to completely eradicate angiogenic
VECs. In contrast, ntPDT-treated angiogenic HMVEC
formed similar numbers of colonies as untreated
control cells (p value not significant).
3. Using the half-maximally effective concentration
(EC50) as an indicator, based on clonogenic assay
results, we found that the EC50 of SnCe6 in fVII-
SnCe6 tPDT was 0.031 lM for angiogenic HMVEC,
whereas it had no observable killing effect on normal
quiescent VEC (see Fig. 4f). Taken together, the
results in Fig. 4d, e, f suggested that the fVII-tPDT
is selective and effective in eradicating angiogenic
VECs.
To better understand its mechanism of action of fVII-
tPDT, we first treated angiogenic and resting HMVEC with
cFig. 4 fVII-tPDT is selective and effective in eradicating angiogenic
VEC. a–c fVII-SnCe6 conjugates retains the binding activity and
selectivity to angiogenic VECs (HMVEC). Goat anti-TF was a
positive control (a), SnCe6 was separately conjugated with mfVII/Sp
(b) and mfVII/NLS (c) d Representative imaging of crystal violet-
stained VEGF-stimulated and unstimulated HMVECs right after
being treated with fVII-tPDT or ntPDT (2 lM and 635 nm laser light
at 36 J/cm2). Control HMVECs include an untreated control and a
maximal killing control (completely lysed by 1% Triton X-100).
Original magnification: 4009 phase contrast. e Complete eradication
(no colonies formed) of angiogenic VEC (HMVEC) by fVII-tPDT
using fVII/NLS-SnCe6 or fVII/Sp-SnCe6 (p\ 0.001 vs. untreated
control), whereas ntPDT has no therapeutic effect in killing angio-
genic VEC under the same condition as for fVII-tPDT (2 lM SnCe6
and 635 nm laser light at 36 J/cm2). f The fVII-tPDT is effective and
selective in killing angiogenic VEC (angiogenic HMVEC) with an
EC50 of 0.031 lM SnCe6 in fVII/NLS-SnCe6, whereas it has no side
effects to quiescent VEC (HMVEC). The fVII-tPDT conditions were
as follows: 635 nm laser light at 36 J/cm2 and the SnCe6 concen-
trations in the fVII/NLS-SnCe6 conjugate (x axis) were 0.0 (buffer
only), 0.5, 1 and 2 lM, respectively. Note that the VEC cells without
fVII/NLS-SnCe6 (0.0 lM) also served as the light only control as
they were also irradiated with 635 nm laser light (36 J/cm2). g The
underlining mechanism of fVII/NLS-tPDT involves rapid induction
of apoptosis and necrosis. SnCe6 concentration was reduced to 1 lM
(36 J/cm2) so that not all of the treated cells undergo necrosis
immediately after fVII-tPDT (See the stained HMVEC in d). Annexin
V-FITC (green) stains for apoptotic cell membrane (green arrow) and
propidium iodide (PI, red) stains for the nuclei of dead cells (red
arrows). Original magnification: 4009. p values were calculated by
2-way ANOVA with multiple comparisons test. Data are presented as
Mean ± SD and representative of two or three independent exper-
iments. (Color figure online)
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fVII-tPDT (mfVII/NLS-SnCe6) or ntPDT (SnCe6) then
immediately tested the VEC for apoptosis using Annexin
V-FITC and for necrosis using propidium iodide (PI). We
found that fVII-tPDT treatment induced immediate apop-
tosis and necrosis in angiogenic HMVECs (see Fig. 4g),
similar to its mechanism in killing human lung cancer cells
[6]. Importantly, fVII-tPDT did not induce
detectable apoptosis and necrosis in quiescent HMVEC,
whereas ntPDT had no effect in angiogenic and quiescent
HMVEC (Fig. 4g).
Discussion
Identification of specific anti-angiogenic target molecules
in endothelial is crucial in developing anti-angiogenesis
therapies. Toward this end, a major effort has focused on
targeting VEGF and VEGFRs. Elevated levels of VEGFRs
are detected on tumor VECs in many types of solid cancers
[36]. Unfortunately, VEGFRs are not angiogenic-specific
endothelial receptors since they are also expressed on
normal endothelium in many organs [37, 38]. Nevertheless,
this study defines the peak expression of TF on angiogenic
VECs (4 h VEGF induction), which may be used as an
optimized time point for generating in vitro VEC models
for identification of more novel target molecules by
revealing the differences in gene expression (for example,
mRNAs and micro-RNAs) between angiogenic and qui-
escent VECs.
In this report, we show that, unlike VEGFRs, TF is a
specific receptor for angiogenic VECs in vitro. It appears
that TF is also a unique pathological angiogenic endothelial
cell surface receptor in vivo because of its selective
expression on angiogenic VECs in vivo in tumor vascula-
ture [4–7, 9, 14], ocular [18] and endometriotic [21] neo-
vasculature from patients or animal models. In addition to
TF on angiogenic VEC, TF is overexpressed on many
cancer cells including solid cancer and leukemia [39].
Therefore, TF appears to be a common yet specific bio-
marker and target molecule for both the pathological
neovasculature and cancer cells [6, 7, 16, 39].
Consequently, the use of fVII as targeting vehicle
enabled our group to develop two TF-targeted therapeutics,
namely fVII/IgG1 Fc (ICON) for immunotherapy and fVII/
PS for tPDT, which display selectivity, effectiveness and
safety in the treatment of lung and breast cancer (regardless
of their drug resistance and other membrane targets)
[5–7, 13–17, 23], macular degeneration [18–20] and/or
endometriosis [21] in preclinical mouse, rat and pig models
and in phase I and II clinical trials for AMD patients
(NCT01485588) [22]. In this study, we showed that both
mfVII/IgG1 Fc and hfVII/IgG1 Fc bind to human TF,
which is only expressed by angiogenic VECs upon VEGF
stimulation. Thus, TF-targeted ICON and fVII-tPDT
should not cause side effects to quiescent vessels, including
microvessels, venous and arterial vessels, while they can
selectively target and effectively eradicate angiogenic
VECs via TF targeting. Nevertheless, caution should be
taken as VEGF and other chemokines (IL-1b, TNF-a, etc.)
may potentially induce TF expression on normal resting
VECs. They should be monitored before and during the
treatment of fVII agents, particularly when fVII agents are
administered systemically. In the case of cancer, Drs. Yang
and Rosenberg et al. [40] reported that 76 of 113 patients
with metastatic renal cell carcinoma had a baseline VEGF
level below the lower limit of detection (40 pg/ml). After
anti-VEGF antibody bevacizumab (Avastin) therapy, the
plasma VEGF levels increased to a range of 150–250 pg/
ml. Similarly, a very recent study [41] reported that the
plasma baseline levels of VEGF in 60 patients (Hongkong)
with colorectal cancer metastases were about 10 pg/ml, and
they were increased to 40 pg/ml after anti-VEGF antibody
bevacizumab (Avastin) therapy [41]. Importantly, the
group found that increased VEGF was in a complex with
the neutralizing antibody that prevents VEGF from binding
to VEGF receptors. In the cases of AMD and PCV (poly-
poidal choroidal vasculopathy), Tong et al. [42] reported
that the aqueous humor level of VEGF was about 400 pg/
ml in eyes with PCV and about 700 pg/ml in eyes with
choroidal neovascularization of AMD. A Japanese group
also reported aqueous humor level of VEGF was higher in
AMD and PCV than control eyes. But they did not find the
significant difference of VEGF levels between AMD and
PCV. Nevertheless, the levels of VEGF reported in those
published studies were at 100-fold lower than the con-
centration (1 nM VEGF = 38 ng/ml, MW 38 kDa) that we
tested in this study. It remains to investigate the lowest
VEGF concentration that is able to induce endothelial TF
expression. If the blood VEGF level in patients is detected
high (enough to induce TF expression on normal
endothelial cells), anti-VEGF inhibitors may be adminis-
tered to neutralize and clear VEGF from circulation, if any,
prior to fVII-targeted therapies. Regardless of the VEGF
levels in AMD and PCV, fVII-tPDT may be used for the
treatment of these ocular diseases as long as TF expression
is detected in the neovascularization lesions.
In conclusion, this study identifies that TF is an angio-
genic-specific endothelial biomarker and verifies that TF is
the therapeutic target specific for fVII agents. This study
also elucidated for the first time that the specificity of fVII
agents for angiogenic VEC is mediated via binding TF.
Thus, this study not only identifies TF as an angiogenic
endothelial receptor specific for fVII agents, but also helps
predict therapeutic efficacy and potential side effects of
these fVII-targeted agents. As such, supports use of TF-
targeted therapeutics in clinical trials of several
94 Angiogenesis (2017) 20:85–96
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angiogenesis-dependent common human diseases, notably
cancer, macular degeneration, endometriosis and rheuma-
toid arthritis, in which VEGF plays a central role in
pathological angiogenesis.
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